An important step in simplifying asthma and chronic obstructive pulmonary disease (COPD)
management and improving adherence with prescribed therapy is to reduce the dose …

Bronchodilators are central in the treatment of of airways disorders. They are the mainstay of
the current management of chronic obstructive pulmonary disease (COPD) and are critical in …

After the discovery of formoterol and salmeterol, new candidates for long-acting β2-
adrenoceptor agonists (LABAs) have emerged from various companies. In particular, once …

Despite the passionate debate over the use of β2‐adrenoceptor agonists in the treatment of
airway disorders, these agents are still central in the symptomatic management of asthma …

Bronchodilators remain the cornerstone of the treatment of airway disorders such as asthma
and chronic obstructive pulmonary disease (COPD). There is therefore considerable interest …

Bronchodilators are central in the symptomatic management of asthma. It is likely that the
once-daily dosing of a bronchodilator would be a significant convenience and probably a …

There has been a real interest recently in developing once-daily β2-adrenoceptor agonists
(ultra-long-acting β 2-adrenoceptor agonists [ultra-LABAs]) for treating asthma and chronic …

Background: The proven efficacy of several anti-cholinergics and β2-agonists and their
combinations in both chronic obstructive pulmonary disease (COPD) and asthma strongly …

Bronchodilators remain central to the symptomatic management of chronic obstructive
pulmonary disease and asthma, and, for this reason and also because the patent protection …

Inhaled bronchodilators, including long-acting muscarinic receptor antagonists (LAMA) and
long-acting β2-adrenoreceptor agonists (LABA), are the mainstay of pharmacological …